Bumper Offer - Urjas oil Just @ Rs. 1
Vomilast OD is an allopathic medicine The correct dosage of Vomilast OD depends on the patient's age, gender, and medical history. This information has been provided in detail in the dosage section.
Vomilast OD is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult(Female) |
|
Based on research, the following side effects have been observed when Vomilast OD is used -
Severe
Moderate
Mild
Is the use of Vomilast OD safe for pregnant women?
Vomilast OD is safe for pregnant women.
Is the use of Vomilast OD safe during breastfeeding?
Vomilast OD is completely safe for breastfeeding women.
What is the effect of Vomilast OD on the Kidneys?
Vomilast OD does not damage the kidneys.
What is the effect of Vomilast OD on the Liver?
Vomilast OD does not damage the liver.
What is the effect of Vomilast OD on the Heart?
There are no any side effects of Vomilast OD for the heart.
Vomilast OD should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Vomilast OD unless your doctor advises you to do so -
Is this Vomilast OD habit forming or addictive?
Forming a habit of Vomilast OD has not been reported.
Interaction between Food and Vomilast OD
Some foods when eaten with Vomilast OD can alter the onset of actions. Discuss this with your doctor.
Interaction between Alcohol and Vomilast OD
No research has been done on this till date. Therefore, it is not known what the effect of taking Vomilast OD with alcohol will be.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 469
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 663
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Bonjesta (doxylamine succinate and pyridoxine hydrochloride)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Bonjesta (doxylamine succinate and pyridoxine hydrochloride)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclegis (doxylamine succinate and pyridoxine hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 609-611
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 469
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 663
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Bonjesta (doxylamine succinate and pyridoxine hydrochloride)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Bonjesta (doxylamine succinate and pyridoxine hydrochloride)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Diclegis (doxylamine succinate and pyridoxine hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 609-611
